Caroline Godfrey
Corporate Officer/Principal chez Pepgen Ltd.
Provenance du réseau au premier degré de Caroline Godfrey
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 9 | |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom.
3
| Subsidiary | Packaged Software | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Caroline Godfrey via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
LA JOLLA PHARMACEUTICAL COMPANY | Pharmaceuticals: Major | Comptroller/Controller/Auditor | |
BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Corporate Officer/Principal | |
H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Director of Finance/CFO | |
Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Biotechnology | Founder | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Araxes Pharma LLC
Araxes Pharma LLC Pharmaceuticals: MajorHealth Technology Araxes Pharma LLC develops drugs for the treatment of cancer and other diseases. The private company is based in La Jolla, CA. | Pharmaceuticals: Major | Director of Finance/CFO | |
WAVE LIFE SCIENCES LTD. | Biotechnology | Corporate Officer/Principal | |
SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Wake Forest University | College/University | Doctorate Degree | |
University of Cambridge | College/University | Graduate Degree | |
McGill University | College/University | Doctorate Degree | |
Babson College | College/University | Masters Business Admin | |
University of Bristol | College/University | Doctorate Degree | |
University College London | College/University | Doctorate Degree | |
University of Southern Denmark | College/University | Doctorate Degree | |
The Association of Bioscience Financial Officers
The Association of Bioscience Financial Officers Miscellaneous Commercial ServicesCommercial Services The Association of Bioscience Financial Officers operates as a national networking group for biotechnology, med tech and bioscience financial officers. The company was founded in 1988 and is headquartered in Menlo Park, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
San Diego Children's Choir | Director of Finance/CFO | ||
ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Lucknow | College/University | Undergraduate Degree | |
University of Massachusetts Lowell | College/University | Undergraduate Degree | |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Medical Distributors | Founder | |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | Information Technology Services | Director/Board Member | |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Biotechnology | Founder | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Biotechnology | Director of Finance/CFO | |
FULCRUM THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Respivant Sciences, Inc.
Respivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Respivant Sciences, Inc. is a clinical-stage biopharmaceutical company that develops therapies for patients with respiratory diseases. The company is based in San Diego, CA. | Pharmaceuticals: Major | Director of Finance/CFO | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. BiotechnologyHealth Technology T-Cure Bioscience, Inc. is an innovative immuno-oncology company based in Sherman Oaks, CA. The private company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. The CEO of the company is Gang Zeng. | Biotechnology | Director/Board Member | |
ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Chief Executive Officer | |
PARDES BIOSCIENCES, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
LISATA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
PERSPECTIVE THERAPEUTICS, INC. | Medical Specialties | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 35 |
Royaume-Uni | 10 |
Danemark | 4 |
Singapour | 2 |
Canada | 2 |
Sectorielle
Health Technology | 34 |
Consumer Services | 10 |
Commercial Services | 4 |
Distribution Services | 2 |
Technology Services | 2 |
Opérationnelle
Director/Board Member | 24 |
Corporate Officer/Principal | 18 |
Director of Finance/CFO | 12 |
Chief Tech/Sci/R&D Officer | 12 |
Founder | 11 |
Relations les plus connectées
- Bourse
- Insiders
- Caroline Godfrey
- Connexions Sociétés